Wealth Enhancement Advisory Services’s Atrium Therapeutics RNA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$96.7K	Buy	+11,709	New	+$138K	﹤0.01%	3949

Other funds holding RNA

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Wealth Enhancement Advisory Services's RNA Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 11,709 shares worth $96.7K. The stake represents ﹤0.01% of the portfolio and ranks #3949 among its holdings.

12 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

Wealth Enhancement Advisory Services held 11,709 shares of Atrium Therapeutics worth $96.7K as of Q3 2026.
Atrium Therapeutics was a new Wealth Enhancement Advisory Services position in Q3 2026.
Atrium Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3949 holding.
12 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.